494.46
Argen X Se Adr stock is traded at $494.46, with a volume of 713.42K.
It is up +1.67% in the last 24 hours and up +10.90% over the past month.
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
See More
Previous Close:
$486.33
Open:
$476.04
24h Volume:
713.42K
Market Cap:
$29.57B
Revenue:
$1.41B
Net Income/Loss:
$-327.78M
P/E Ratio:
-118.86
EPS:
-4.16
Net Cash Flow:
$-910.55M
1W Performance:
+4.91%
1M Performance:
+10.90%
6M Performance:
+29.24%
1Y Performance:
-5.09%
Argen X Se Adr Stock (ARGX) Company Profile
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
Jul-31-23 | Initiated | Scotiabank | Sector Perform |
Jul-24-23 | Downgrade | UBS | Buy → Neutral |
Jul-17-23 | Resumed | Evercore ISI | Outperform |
Jun-15-23 | Initiated | Societe Generale | Sell |
May-31-23 | Initiated | UBS | Buy |
Apr-25-23 | Initiated | Citigroup | Buy |
Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
Dec-07-22 | Initiated | William Blair | Outperform |
Oct-12-22 | Initiated | Oppenheimer | Perform |
Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jun-28-22 | Resumed | Stifel | Buy |
May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-08-21 | Initiated | Wells Fargo | Overweight |
Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
Oct-07-21 | Initiated | Jefferies | Buy |
Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jul-23-21 | Initiated | Deutsche Bank | Hold |
Jul-19-21 | Resumed | Wolfe Research | Outperform |
Jun-18-21 | Initiated | UBS | Buy |
Jun-04-21 | Resumed | Robert W. Baird | Outperform |
May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Apr-23-21 | Initiated | Redburn | Neutral |
Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
Aug-25-20 | Initiated | Raymond James | Outperform |
Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
Feb-10-20 | Initiated | BofA/Merrill | Buy |
Nov-05-19 | Initiated | Credit Suisse | Neutral |
Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
Oct-22-19 | Initiated | JP Morgan | Overweight |
Sep-27-19 | Initiated | Wells Fargo | Market Perform |
Sep-16-19 | Resumed | Cowen | Outperform |
Jun-28-19 | Initiated | Robert W. Baird | Outperform |
Jan-18-19 | Resumed | SunTrust | Buy |
Jan-04-19 | Initiated | Morgan Stanley | Overweight |
Dec-17-18 | Initiated | Goldman | Buy |
Dec-14-18 | Initiated | Wolfe Research | Outperform |
Jun-29-18 | Initiated | Nomura | Buy |
Apr-09-18 | Initiated | SunTrust | Buy |
Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
argenx shares target lifted on revenue growth prospects - Investing.com
Investing.com
Argenx Is Expanding Its Autoimmune Portfolio With New Vyvgart Approvals and Pipeline Candidates - Morningstar
Morningstar
Earnings call: Argenx reported an operating income of $489 million - Investing.com India
Investing.com India
Earnings call: Argenx reported an operating income of $489 million - Investing.com
Investing.com
argenx ADR Getting Closer To Key Technical Benchmark - Investor's Business Daily
Investor's Business Daily
Oppenheimer upgrades argenx stock rating on CIDP indication - Investing.com
Investing.com
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):